secwatch.observer — SEC 8-K summary
======================================

Issuer:     Clene Inc. (CLNN)
CIK:        0001822791
Form:       8-K
Filed at:   2023-05-12T23:59:59+00:00
Accession:  0001437749-23-014227
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Clene reports Q1 net loss of $11.8M, cash $18.4M; ALS data milestones expected mid-2023
--------------------------------------------------------------------------------

- Net loss $11.8M ($0.15/sh) vs $13.4M ($0.21/sh) in Q1 2022; R&D $7.4M, G&A $3.4M.
- Cash and marketable securities $18.4M as of Mar 31, expected to fund ops into Q3 2023.
- ALS survival benefit data from HEALEY and RESCUE-ALS trials presented at AAN; biomarker/long-term survival data expected mid-2023.
- Appointed Benjamin Greenberg, M.D., as Head of Medical; entered $25M equity facility with Lincoln Park.
- MS regulatory discussions anticipated in Q4 2023; advancing partnership opportunities.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1822791/000143774923014227/0001437749-23-014227-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1822791/000143774923014227/clnn20230505_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-014227

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer